AI Engines For more Details: Perplexity Kagi Labs You
Anthelmintic Activity: Oxfendazole belongs to the benzimidazole class of anthelmintic drugs. It works by disrupting the parasites' ability to absorb glucose, leading to their paralysis and eventual death. It is effective against a wide range of gastrointestinal parasites, including roundworms, hookworms, whipworms, and certain tapeworms, in various animal species.
Indications in Animals: Oxfendazole is commonly used in veterinary medicine to treat parasitic infections in livestock such as cattle, sheep, goats, and swine, as well as in horses and other companion animals. It is effective against both adult and larval stages of parasitic worms.
Dosage and Administration: The dosage and administration of oxfendazole in animals vary depending on the species, weight, and type of parasite being targeted. It is typically administered orally as a paste, suspension, or bolus. Dosage instructions should be followed carefully according to the veterinarian's recommendations.
Safety and Side Effects in Animals: Oxfendazole is generally well-tolerated in animals when used as directed. However, adverse effects such as gastrointestinal upset (e.g., diarrhea, vomiting), allergic reactions, or neurological signs (e.g., tremors, ataxia) may occur in some cases, particularly with overdose or hypersensitivity reactions.
Withdrawal Periods: In food-producing animals such as cattle, sheep, and goats, there are specific withdrawal periods that must be observed after treatment with oxfendazole to ensure that residues do not exceed safe levels in meat, milk, or other animal-derived products intended for human consumption. These withdrawal periods vary depending on the country and regulatory guidelines.
Safety Considerations in Humans: While oxfendazole is primarily intended for veterinary use, accidental exposure or ingestion by humans can occur, particularly among individuals handling the medication or coming into contact with treated animals. In such cases, precautions should be taken to avoid direct skin contact or ingestion, and medical advice should be sought if exposure occurs.
Resistance: Like other anthelmintic drugs, resistance to oxfendazole has been reported in certain parasite populations, particularly with frequent or improper use. To mitigate the development of resistance, proper dosing, rotation of anthelmintic classes, and other integrated parasite management practices should be implemented.
Consultation with a Veterinarian: Use of oxfendazole in animals should always be carried out under the guidance of a qualified veterinarian who can provide appropriate diagnosis, treatment recommendations, and advice on parasite control strategies tailored to the specific needs of the individual animal or herd/flock.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.1 | 0.1 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 2.4 | 0.3 | 7 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 1.8 | 1 | 0.8 |
| Allergies | 2 | 1.2 | 0.67 |
| Allergy to milk products | 1.4 | 0.6 | 1.33 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 2.7 | 3.5 | -0.3 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.9 | 0.3 | 5.33 |
| Ankylosing spondylitis | 2.5 | 0.9 | 1.78 |
| Anorexia Nervosa | 1.2 | 2.3 | -0.92 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.4 | |
| Asthma | 3.7 | 1.7 | 1.18 |
| Atherosclerosis | 1.2 | 1 | 0.2 |
| Atrial fibrillation | 2.7 | 0.6 | 3.5 |
| Autism | 4.1 | 4.7 | -0.15 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.6 | 0.6 | |
| Bipolar Disorder | 0.8 | 1.4 | -0.75 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Cancer (General) | 0.6 | 0.8 | -0.33 |
| Carcinoma | 2.5 | 2.2 | 0.14 |
| Celiac Disease | 1.2 | 2.9 | -1.42 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 2.1 | 3 | -0.43 |
| Chronic Kidney Disease | 1.7 | 1.7 | 0 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1 | 1.7 | -0.7 |
| Chronic Urticaria (Hives) | 0.8 | 0 | 0 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 1.3 | -3.33 |
| Cognitive Function | 2 | 1.6 | 0.25 |
| Colorectal Cancer | 2.7 | 1.6 | 0.69 |
| Constipation | 0.9 | 0.7 | 0.29 |
| Coronary artery disease | 0.9 | 1.8 | -1 |
| COVID-19 | 3.5 | 4.9 | -0.4 |
| Crohn's Disease | 3.8 | 3.7 | 0.03 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.3 | -1.3 | |
| deep vein thrombosis | 0.3 | 1.4 | -3.67 |
| Denture Wearers Oral Shifts | 1 | 1 | |
| Depression | 4.3 | 4.4 | -0.02 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.8 | 0.9 | -0.13 |
| Endometriosis | 1.9 | 2 | -0.05 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 1.3 | 0.7 | 0.86 |
| erectile dysfunction | 0.5 | 0.3 | 0.67 |
| Fibromyalgia | 2.1 | 0.9 | 1.33 |
| Functional constipation / chronic idiopathic constipation | 2.9 | 2.3 | 0.26 |
| gallstone disease (gsd) | 1.5 | 0.8 | 0.88 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.7 | -1.33 |
| Generalized anxiety disorder | 1 | 1.8 | -0.8 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.5 | 0.5 | 2 |
| Graves' disease | 1.5 | 3.3 | -1.2 |
| Gulf War Syndrome | 0.9 | 0.4 | 1.25 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 2.7 | 1.1 | 1.45 |
| Heart Failure | 1.8 | 1.3 | 0.38 |
| hemorrhagic stroke | 0.6 | 0.6 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 0.8 | 0.6 | 0.33 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
| hyperglycemia | 0.7 | 0.7 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 2.7 | 3.4 | -0.26 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 1.4 | 0.3 | 3.67 |
| IgA nephropathy (IgAN) | 0.9 | 2.8 | -2.11 |
| Inflammatory Bowel Disease | 2.4 | 3.9 | -0.63 |
| Insomnia | 2 | 2.1 | -0.05 |
| Intelligence | 0.8 | 0 | 0 |
| Intracranial aneurysms | 0.7 | 0.6 | 0.17 |
| Irritable Bowel Syndrome | 3.9 | 3.4 | 0.15 |
| ischemic stroke | 2 | 0.8 | 1.5 |
| Liver Cirrhosis | 4.2 | 3.1 | 0.35 |
| Long COVID | 2.7 | 4.5 | -0.67 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1 | -1 | |
| Mast Cell Issues / mastitis | 0.3 | 0.9 | -2 |
| ME/CFS with IBS | 0.5 | 1 | -1 |
| ME/CFS without IBS | 0.5 | 1.3 | -1.6 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1 | 0.5 | 1 |
| Metabolic Syndrome | 3.5 | 4.3 | -0.23 |
| Mood Disorders | 4.3 | 3.8 | 0.13 |
| multiple chemical sensitivity [MCS] | 0.7 | 0.1 | 6 |
| Multiple Sclerosis | 2.4 | 3 | -0.25 |
| Multiple system atrophy (MSA) | 0 | 0.7 | 0 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 1.8 | -1.8 | |
| Neuropathy (all types) | 0.4 | 0.8 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.8 | 3 | 0.27 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 4.9 | 4.4 | 0.11 |
| obsessive-compulsive disorder | 1.6 | 2.5 | -0.56 |
| Osteoarthritis | 1.2 | 1.2 | 0 |
| Osteoporosis | 1.6 | 1.3 | 0.23 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 3.1 | 3.8 | -0.23 |
| Polycystic ovary syndrome | 2.5 | 2.4 | 0.04 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.7 | |
| primary biliary cholangitis | 1.2 | 0.8 | 0.5 |
| Primary sclerosing cholangitis | 1.7 | 1.1 | 0.55 |
| Psoriasis | 1.7 | 1.1 | 0.55 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4 | 3.2 | 0.25 |
| Rosacea | 0.9 | 0.7 | 0.29 |
| Schizophrenia | 4 | 2.6 | 0.54 |
| scoliosis | 0.3 | 0.7 | -1.33 |
| Sjögren syndrome | 1.6 | 1.3 | 0.23 |
| Sleep Apnea | 1.9 | 1.6 | 0.19 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 0.4 | 2.5 |
| Stress / posttraumatic stress disorder | 1.9 | 1.7 | 0.12 |
| Systemic Lupus Erythematosus | 1.8 | 1.8 | 0 |
| Tic Disorder | 0.9 | 1.2 | -0.33 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 2.1 | 3 | -0.43 |
| Type 2 Diabetes | 3.3 | 3.7 | -0.12 |
| Ulcerative colitis | 2.7 | 2.6 | 0.04 |
| Unhealthy Ageing | 2 | 1.4 | 0.43 |
| Vitiligo | 1.5 | 0.6 | 1.5 |
